An important part of managing pulmonary arterial hypertension is working with a specialist who understands this rare and ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...

United Therapeutics recently announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational miroliverELAP external liver assist product, which uses ...

Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...

Rivers-born Nigerian environmental scientist, Suka Momta, has unveiled what he calls solution to global environment pollution ...

With wit, urgency, and unforgettable music, this Tony Award–winning musical brings to life the messy, human, and deeply dramatic birth of America. Alongside Benjamin Franklin an ...

Ten years later, an investigation to why a 30-year-old Aberdeen woman vanished remains open. Police say the smallest new ...

Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.

AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...

The strongest inverse correlations between the risk of pulmonary arterial hypertension and the levels of fatty acids were recorded for polyunsaturated fatty acids, omega-3, and docosahexaenoic acid.

New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...

SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased ...